FABP5 and hepatocellular carcinoma: To elucidate the anti‐tumor efficacy of targeting tumor cell‐intrinsic FABP5 co‐delivery nanocarriers combined with RFA treatment in HCC, nanoparticles were categorized into four groups based on their composition in subsequent experiments: RP:@RBCM/cRGD‐phLips (control group), SRP:SPIO@RBCM/cRGD‐phLips, FRP:sgFABP5@RBCM/cRGD‐phLips, and FSRP:FS@RBCM/cRGD‐phLips.